The nuclear medicine software market was valued at USD 970.03 million in 2025 and is estimated to reach USD 1.49 billion by 2030, registering a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine software market is being influenced by a convergence of clinical and technological advancements, along with favorable regulatory and reimbursement frameworks in developed and developing nations. These technological advancements are significantly transforming how nuclear medicine imaging and radiopharmaceutical therapies are delivered. Key factors driving growth include the increasing demand for accurate image analysis, PACS integration, dosimetry, treatment planning, advanced analytics, and reporting.
In addition to the growing demand in the diagnostic imaging segment, nuclear medicine therapeutic applications are seeing an increase in the adoption rates of theranostics. Leading market players are increasingly integrating their solutions with AI-powered tools for tumor segmentation and automated reporting, thereby enhancing diagnostic accuracy and workflow efficiency. The pharmaceutical and life sciences sectors are fueling the demand for advanced nuclear medicine software solutions due to the expanding pipeline of radiopharmaceuticals. Furthermore, the growing transition towards cloud-native PACS integration and remotely accessible solutions is promoting the development of advanced software solutions. However, the growth of this market is moderately restrained due to challenges arising from data security, inadequate infrastructure, and radiation exposure.
Furthermore, healthcare systems are transitioning towards a value-based care approach, in which cloud-developed infrastructure supports integrated decision-making, thereby enhancing overall patient care. Moreover, the adoption of advanced nuclear medicine workflows requires cloud-based software platforms that can synchronize imaging and treatment planning. Some companies offering cloud-native platforms include Sectra’s Cloud Imaging Platform and Intelerad’s IntelePACS Cloud. These solutions support PET/SPECT viewing and reporting, seamlessly integrating with AI modules for remote accessibility.
SaaS models provide regular software updates with predictable operational costs and seamlessly integrate with cloud-native PACS and radiology systems, thereby supporting hospitals and imaging centers in modernizing their nuclear imaging workflows. With the expansion of multi-site imaging networks, SaaS platforms enable centralized data access, interoperable workflows, and remote access diagnostics. Some of the leading market players offering their solutions through subscription-based SaaS models are GE Healthcare and Siemens Healthineers.
This growth is attributed to rising public and private investments in precision medicine, an escalating disease burden from cancer and cardiovascular diseases, and advancements in infrastructure across China, India, Japan, Australia, and South Korea. Furthermore, the region is experiencing rapid adoption of personalized dosimetry and theranostics, alongside increasing partnerships between local hospitals and globally established companies. Growing patient awareness, rising healthcare IT expenditure, and the increasing adoption of AI-based imaging solutions are further boosting growth in the Asia Pacific market.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine software marketplace.
Players adopted both organic and inorganic growth strategies, including product launches and enhancements, as well as investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances. These strategies aimed to increase their offerings, meet the unmet needs of customers, boost profitability, and expand their presence globally market.
The study includes an in-depth competitive analysis of these key players in the nuclear medicine software market, with their company profiles, recent developments, and key market strategies.
In addition to the growing demand in the diagnostic imaging segment, nuclear medicine therapeutic applications are seeing an increase in the adoption rates of theranostics. Leading market players are increasingly integrating their solutions with AI-powered tools for tumor segmentation and automated reporting, thereby enhancing diagnostic accuracy and workflow efficiency. The pharmaceutical and life sciences sectors are fueling the demand for advanced nuclear medicine software solutions due to the expanding pipeline of radiopharmaceuticals. Furthermore, the growing transition towards cloud-native PACS integration and remotely accessible solutions is promoting the development of advanced software solutions. However, the growth of this market is moderately restrained due to challenges arising from data security, inadequate infrastructure, and radiation exposure.
Cloud-native platforms are expected to register the fastest growth over the forecast period.
The lucrative growth of cloud-native platforms is attributed to the increasing demand for remote access, interoperability, and scalability across healthcare systems. Nuclear medicine is rapidly evolving through multi-center collaborations and AI-powered analytics, driving the need for cloud-native solutions. These platforms enable real-time data sharing, faster software updates, and enhanced cybersecurity features.Furthermore, healthcare systems are transitioning towards a value-based care approach, in which cloud-developed infrastructure supports integrated decision-making, thereby enhancing overall patient care. Moreover, the adoption of advanced nuclear medicine workflows requires cloud-based software platforms that can synchronize imaging and treatment planning. Some companies offering cloud-native platforms include Sectra’s Cloud Imaging Platform and Intelerad’s IntelePACS Cloud. These solutions support PET/SPECT viewing and reporting, seamlessly integrating with AI modules for remote accessibility.
The subscription-based/Software-as-a-service (SaaS) models segment held the largest share of the nuclear medicine software market in 2024.
The subscription-based Software-as-a-Service (SaaS) model segment dominates the software licensing segment in the nuclear medicine software market in 2024. This dominance is due to the lower upfront costs, flexibility, and cloud-based deployments offered by this model. Healthcare providers, life sciences companies, and research institutes are increasingly shifting from traditional perpetual licensing models because of the high capital expenditures and limited scalability associated with them.SaaS models provide regular software updates with predictable operational costs and seamlessly integrate with cloud-native PACS and radiology systems, thereby supporting hospitals and imaging centers in modernizing their nuclear imaging workflows. With the expansion of multi-site imaging networks, SaaS platforms enable centralized data access, interoperable workflows, and remote access diagnostics. Some of the leading market players offering their solutions through subscription-based SaaS models are GE Healthcare and Siemens Healthineers.
North America market accounts for the largest share in the nuclear medicine software market in 2024.
The North American market dominated the nuclear medicine software sector in 2024, due to its advanced healthcare infrastructure, increasing adoption of hybrid imaging systems, and strong regulatory support for radiopharmaceutical-based diagnostics and therapeutics. Additionally, the significant presence of market leaders such as GE Healthcare and Siemens Healthineers contributes to the growth of the North American market. In contrast, the Asia Pacific market is expected to register the fastest growth rate over the forecast period.This growth is attributed to rising public and private investments in precision medicine, an escalating disease burden from cancer and cardiovascular diseases, and advancements in infrastructure across China, India, Japan, Australia, and South Korea. Furthermore, the region is experiencing rapid adoption of personalized dosimetry and theranostics, alongside increasing partnerships between local hospitals and globally established companies. Growing patient awareness, rising healthcare IT expenditure, and the increasing adoption of AI-based imaging solutions are further boosting growth in the Asia Pacific market.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine software marketplace.
The breakdown of primary participants is as mentioned below:
- By Company Type - Tier 1 (31%), Tier 2 (31%), and Tier 3 (28%)
- By Designation - C-level Executives (44%), Director-level (31%), and Managers (25%)
- By Region - North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), and Middle East & Africa (3%)
Key Players in the Nuclear Medicine Software Market
Prominent players in the nuclear medicine software market include include GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG(Germay), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Brainlab AG(Germany), Mirada Medical(UK), DOSIsoft SA(France), Bracco Group (Italy), Hermes Medical Solutions (Sweden), INVIA, LLC (US), Mediso Ltd. (Hungary), Canon Medical Systems Corporation (Japan), LabLogic Systems Ltd. (UK), Mirion Technologies (ec2 Software Solutions)(US), COMECER S.p.A.(Italy), RaySearch Laboratories(Sweden), UltraSPECT Inc. (US), Sectra AB (Sweden), Agfa-Gevaert Group (Belgium), Perceptive(UK).Players adopted both organic and inorganic growth strategies, including product launches and enhancements, as well as investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances. These strategies aimed to increase their offerings, meet the unmet needs of customers, boost profitability, and expand their presence globally market.
The study includes an in-depth competitive analysis of these key players in the nuclear medicine software market, with their company profiles, recent developments, and key market strategies.
Research Coverage
- The report studies the nuclear medicine software market based on software type, workflow, integration complexity, software licensing model, revenue model, application, therapeutic area, technology maturity, end user, and region.
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
- The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
- The report studies micromarkets with respect to their growth trends, prospects, and contributions to the total nuclear medicine software market.
- The report forecasts the revenue of market segments with respect to five major regions.
Reasons to Buy the Report
The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.This report provides insights into the following pointers:
- Analysis of key drivers (increasing demand for early and accurate diagnostics, growing focus on personalized medicine, integration of automated dosimetry tools, growing prevalence of chronic diseases and subsequent increase in clinical trials, effective monitoring of nuclear medicine software), restraints (high cost of imaging equipment, data privacy and security concerns, shortage of skilled professionals, interpolability issues), opportunities (infrastructure development, increased healthcare IT expenditure, data privacy and regulatory reforms), and challenges (compliance requirements, low penetration of advanced imaging devices, underdeveloped radiopharmcy ecosysytem, economic and financial barriers) influencing the industry macrodynamics of nuclear medicine software market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine software market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine software across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine software market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine software market.
Table of Contents
1 Introduction
2 Research Methodology
4 Premium Insights
5 Market Overview
6 Nuclear Medicine Software Market, by Software Type
7 Nuclear Medicine Software Market, by Workflow
8 Nuclear Medicine Software Market, by Integration Complexity
9 Nuclear Medicine Software Market, by Software Licensing
10 Nuclear Medicine Software Market, by Revenue Model
11 Nuclear Medicine Software Market, by Application
12 Nuclear Medicine Software Market, by Therapeutic Area
13 Nuclear Medicine Software Market, by Technology Maturity
14 Nuclear Medicine Software Market, by End-user
15 Nuclear Medicine Software Market, by Region
16 Competitive Landscape
17 Company Profiles
18 Appendix
List of Tables
List of Figures
Companies Mentioned
- Ge Healthcare
- Siemens Healthineers Ag
- Koninklijke Philips N.V.
- Lantheus
- Canon Medical Systems Corporation
- Mirion Technologies, Inc.
- Brainlab Ag
- Mirada Medical Limited
- Dosisoft Sa
- Bracco Group
- Hermes Medical Solutions
- Invia, LLC
- Mediso Ltd.
- Lablogic Systems Ltd.
- Comecer S.P.A. Private
- Raysearch Laboratories
- Ultraspect Inc.
- Sectra Ab
- Agfa-Gevaert Group
- Perceptive
- Syntermed Inc.
- Segami Corporation
- Versant Medical Physics & Radiation Safety
- Pixmeo
- Paire
- Subtle Medical, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 465 |
| Published | July 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value in 2025 | 970.03 Million |
| Forecasted Market Value by 2030 | 1491.6 Million |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
